Literature DB >> 29961573

Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction.

Thor Ueland1, Ola Kleveland2, Annika E Michelsen3, Rune Wiseth2, Jan Kristian Damås4, Kirsten B Holven5, Pål Aukrust6, Lars Gullestad7, Arne Yndestad8, Bente Halvorsen3.   

Abstract

BACKGROUND: The IL-6 receptor antagonist tocilizumab has been shown to attenuate the proatherogenic lipoprotein a [Lp(a)] in rheumatoid arthritis. We evaluated if a single dose of tocilizumab reduced Lp(a) in patients with non-ST-elevation myocardial infarction (NSTEMI).
METHODS: Lp(a) was assessed by immunoassay (n = 117 patients) at 7 consecutive time-points between day 1 and 3 and at 3 and 6 months follow-up.
RESULTS: Tocilizumab did not affect Lp(a) at any time-point during the study and was not associated with cardiovascular risk factors.
CONCLUSIONS: Short-time inhibition of IL-6 with tocilizumab in patients with NSTEMI did not influence Lp(a) levels.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Acute coronary syndrome; IL-6 antagonism; Inflammation; Lipoprotein(a)

Mesh：

Substances：

Year:  2018        PMID： 29961573     DOI： 10.1016/j.ijcard.2018.06.093

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


  7 in total

1.  The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels.

Authors:  Tina Levstek; Nik Podkrajšek; Andreja Rehberger Likozar; Miran Šebeštjen; Katarina Trebušak Podkrajšek
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-22

Review 2.  Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation.

Authors:  Gissette Reyes-Soffer; Marit Westerterp
Journal:  Pharmacol Res       Date:  2021-05-23       Impact factor: 10.334

3.  Elevated lipoprotein (a) levels are associated with the acute myocardial infarction in patients with normal low-density lipoprotein cholesterol levels.

Authors:  Gaojun Cai; Zhiying Huang; Bifeng Zhang; Lei Yu; Li Li
Journal:  Biosci Rep       Date:  2019-04-05       Impact factor: 3.840

4.  Levels of Lipoprotein (a) in patients with coronary artery disease with and without inflammatory rheumatic disease: a cross-sectional study.

Authors:  Sverre Holm; Ingvild Oma; Tor-Arne Hagve; Kjell Saatvedt; Frank Brosstad; Knut Mikkelsen; Hans Rydningen; Ivar Risnes; Sven Martin Almdahl; Thor Ueland; Pål Aukrust; Bente Halvorsen; Ivana Hollan
Journal:  BMJ Open       Date:  2019-05-10       Impact factor: 2.692

5.  Meta-analysis reveals inhibition of the inflammatory cytokine IL-6 affords limited protection post-myocardial ischemia/infarction.

Authors:  Sushmitha Duddu; Mohan Agrawal; Rituparna Chakrabarti; Anuran Ghosh; Nishant Chakravorty; Ashutosh Tiwari; Praphulla Chandra Shukla
Journal:  Heliyon       Date:  2022-08-28

Review 6.  Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels.

Authors:  Nathaniel Eraikhuemen; Dovena Lazaridis; Matthew T Dutton
Journal:  Am J Cardiovasc Drugs       Date:  2021-05       Impact factor: 3.571

7.  Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI).

Authors:  Anne Kristine Anstensrud; Sindre Woxholt; Kapil Sharma; Kaspar Broch; Bjørn Bendz; Svend Aakhus; Thor Ueland; Brage H Amundsen; Jan Kristian Damås; Einar Hopp; Ola Kleveland; Knut Haakon Stensæth; Anders Opdahl; Nils-Einar Kløw; Ingebjørg Seljeflot; Geir Øystein Andersen; Rune Wiseth; Pål Aukrust; Lars Gullestad
Journal:  Open Heart       Date:  2019-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.